Dr. Anne Gangloff is a Clinical University Researcher and Assistant Professor at Laval University.  She is also a Clinical Researcher at FRQS, Regular Researcher at the Cancer Research Centre at Laval U and Associate Researcher in the Endocrinology and Nephrology axis of the CHU de Québec-Université Laval Research Center. Dr. Gangloff is a physician specializing in laboratory medicine, including clinical pathology and medical biochemistry and is a doctor at the CHUL Lipid Diseases Clinic. She treats both pediatric and adult dyslipidemic patients and also treats patients with cardiovascular diseases. Dr. Gangloff's research interests include cholesterol and its role in cancer progression.

Dr. Christina Ai-Kheng Kim is an assistant professor of internal medicine at the Max Rady College of Medicine at the University of Manitoba. Dr. Kim serves as the research director for the medical oncology residency program committee. She is also a medical oncologist at CancerCare Manitoba. Dr. Kim was awarded a Canadian Institute of Health Research (CIHR) and Canadian Association of Medical Oncologists (CAMO)-funded fellowship focused on symptom burden and prognostic and predictive markers in pancreatic cancer. Dr. Kim is an active member of the gastrointestinal and breast disease site groups at CancerCare Manitoba. She is also one of two clinical leads of the novel Manitoba hereditary gastrointestinal cancer clinic. Dr. Kim’s research focuses on gastrointestinal cancer. She has a particular interest in pancreatic cancer, including real world treatment patterns, outcomes and chemotherapy-related toxicity.

Dr. Boris Gala-Lopez is an associate professor of surgery, microbiology, immunology, hepatobiliary and multi–organ transplant surgeon at Dalhousie University. He received his medical degree from Havana Institute of Medical Sciences, Cuba, where he continued his medical residency. Further, he obtained his master’s in medical informatics from Erasmus University of Rotterdam in Netherlands, followed by a PhD in Experimental Surgery from University of Alberta. He completed his postdoctoral training in Multi-Organ Transplant Surgery at University of Alberta Hospital before joining Dalhousie University. Dr. Gala-Lopez’s research interests focus on developing new strategies to optimize organ and tissue preservation for transplantation.

Dr. Sylvia Ng completed her medical training at the University of British Columbia, radiation oncology residency training and PhD in Medical Biophysics at the University of Toronto, and fellowship at the University of Texas MD Anderson Cancer Centre. Her clinical interests include pancreatic and hepatobiliary cancers, gastrointestinal cancers, SBRT, and MR-guided radiotherapy. She is the pancreatic cancer MR-LINAC lead at the Sunnybrook Odette Cancer Centre. Her scientific expertise lies in pancreatic cancer, tumor microenvironment, and molecular pharmacology. Dr. Ng has published in the areas of translational research, cancer biology, targeted therapy, drug development, and biomarkers in addition to clinical radiation oncology.

Dr. Masoom Haider is a radiologist and clinician scientist at the University of Toronto in the Joint Department of Medical Imaging. His research focuses on image biomarker validation using multiparametric MRI and CT technologies. His team uses machine learning and artificial intelligence methods combined with imaging biomarkers to develop predictive and prognostic radiomics signatures for pelvic cancers, including prostate, pancreas, kidney and liver cancers.Dr. Haider is the imaging lead on national MRI trials in prostate cancer and has worked on guideline development for the use of multiparametric prostate MRI (mpMRI) for prostate cancer, namely the Pi-Rads standard. He holds a Chair in Artificial Intelligence, Imaging Biomarkers and Radiomics at the Lunenfeld-Tanenbaum Research Institute, Sinai Health System. In the Joint Deptartment of Medical Imaging and Lunenfeld-Tanenbaum Research Institute he leads the AI,  Radiomics and Oncologic Imaging Research Lab and collaborates with oncologists, computer scientists, engineers, radiologists and biomedical physicists.Dr. Haider has held peer-reviewed grants from Prostate Cancer Canada, the Canadian Cancer Society Research Institute, Cancer Care Ontario and the Ontario Institute for Cancer Research for MRI-related prostate and pancreatic cancer research.

Eva Villalba is the Executive Director of the Quebec Cancer Coalition, a non-profit patient advocacy group dedicated to improving the Quebec health-care system for people affected by cancer. Since 2008, she has been involved in health-care charities, advocacy groups and non-profits. She graduated from McGill University with a double major in Psychology and Applied Linguistics, then completed an MBA from HEC Montréal with the objective to apply best business practices to the non-profit sector. Eva is passionate about good governance, public policy, community impact, health-care reform and social innovation. She is a volunteer board member of the Artificial Intelligence Impact Alliance (AIIA) and sees great potential in applying AI and technological innovations to the health-care sector to prevent and improve health outcomes. Eva is the first Quebecker and Canadian to obtain a graduate degree in Value-Based Health Care (VBHC) with an MSc. in Health Care Transformation at the University of Texas at Austin with Professor Elizabeth Teisberg and other VBHC experts. Eva is a fierce patient advocate and believes strongly in the potential of the Quebec health-care system to be a world-class leader in Value-Based Care. Eva has an extensive international network of Value-Based Health Transformation Leaders, has a VBHC Green Belt Certification from VBHC Center Europe and is their official Canadian Ambassador. She is also the co-chair of the Resilient Healthcare Coalition (RHC), a diverse group of health system leaders across the public, private, and non-profit sectors committed to helping Canadian health care systems enhance patient care and improve health outcomes by becoming faster, nimbler, and better able to adapt to future shocks.

Leah Marie Migriño Stephenson has cultivated her consulting expertise to improve how we address complexity through individual transformation, organizational change and systems change. She is passionate about social change. Her experiences as a daughter and caregiver for her late mother motivate Leah. Her late mother was a physician who overcame poverty, war, gender discrimination and other systemic and personal obstacles, who struggled against meningioma and recurrent endometrial cancer, all while remaining focused on ending the suffering of others. As a strategist and lateral thinker who has developed expertise in how to better address the many intractable, complex, multi-sectoral issues we face, Leah helps identify and establish effective approaches for individual, organizational and collaborative action to help achieve needed outcomes. A wide range of frameworks and tools support this work, including but not limited to: Four Frames, Theory U, Appreciative Inquiry, Collective Impact, Liberating Structures and more.

Dr. Erica Tsang is a GI medical oncologist at the Princess Margaret Cancer Centre and an Assistant Professor at the University of Toronto. She completed her Internal Medicine and Medical Oncology training at the University of British Columbia, followed by further training in GI and early phase oncology at the University of California San Francisco. She also completed a Masters of Public Health at Harvard University. Her research interests involve genomics and clinical trials, with a focus on pancreatic cancer.

Valerie Cooper is a Hospice Palliative Care Nurse Practitioner with Home and Community Care Support Services South East. She sees patients in their homes in a variety of geographies, from urban to remote. She works in a shared-care model with patients’ existing primary care providers to support patients with malignancies and end-stage organ diseases to die in their preferred place of death. She lectures in the undergraduate program at Queen’s School of Nursing and has developed and taught an elective undergraduate course on hospice palliative care nursing. She has also contributed to a continuing education course for nurse practitioners on palliative care through the University of Toronto. Valerie is a member of the Dying with Dignity Canada’s Clinician Advisory Council, the Canadian Association of MAiD Assessors and Providers (CAMAP) Provincial and Territorial Advisory Council, as well as the CAMAP National MAiD Curriculum Working Group. She is the chair of her local MAiD Community of Practice, as well as a LEAP facilitator for Pallium Canada. She has spoke across Canada about both palliative care and MAiD

Dr. Breffni Hannon leads the palliative care program at the Princess Margaret Cancer Centre in Toronto. Originally from Ireland, she moved to Canada for a 2-year clinical-research fellowship in palliative care in 2011 and never left! She is a clinician-investigator whose research interests include developing models of early palliative care for patients with advance cancer; exploring the needs of caregivers; and promoting advance care planning.

George Zogopoulos, MD (Toronto), PhD (McGill) is an Associate Professor of Surgery and Oncology at McGill University, a staff surgeon at the McGill University Health Centre (MUHC), and a scientist at the Research Institute of the MUHC and the Rosalind and Morris Goodman Cancer Institute. He is a senior clinical research scholar of the Fonds de recherche du Québec - Santé and recipient of the Michal & Renata Hornstein Career Award for Surgical Excellence, with a translational research program studying the genetics and oncogenomics of pancreaticobiliary cancers. His clinical practice focuses on the surgical treatment of pancreatic, biliary and hepatic malignancies as well as abdominal organ transplantation with an interest in transplant oncology.

Dr. Sharlene Gill is a medical oncologist specializing in gastrointestinal (GI) malignancies at BC Cancer – Vancouver. She received a BSc. in Pharmacy, and MD from the University of British Columbia in 1996 followed by residencies in Internal Medicine and Medical Oncology, subsequently completing a fellowship in Gl Oncology at the Mayo Clinic (Rochester, MN) and a Masters of Public Health from the Harvard School of Public Health (Boston, MA) before returning to Vancouver where she is presently Professor of Medicine at the University of British Columbia. In 2017, she completed an MBA from the Kenan-Flagler School of Business at the University of North Carolina. Her areas of clinical expertise are in colorectal, pancreatic and hepatobiliary cancers. She is actively engaged in education and clinical research, with over 100 peer-reviewed publications and book chapters to her credit.

Dr. Brent Johnston is Professor and Head of the Department of Microbiology & Immunology at Dalhousie University and a Senior Scientist with the Beatrice Hunter Cancer Research Institute. He obtained his PhD from the University of Calgary and completed a postdoctoral fellowship at Stanford University. Dr. Johnston’s research program uses models of cancer and autoimmune disease to understand the role of natural killer T (NKT) cells in regulating immune responses and disease outcomes. Dr. Johnston’s group is currently working to develop cancer therapies that incorporate NKT cell-based immunotherapy in combination with select chemotherapeutics, oncolytic viruses, and immune checkpoint antibodies.

Filomena is the President and CEO of the Colorectal Cancer Resource & Action Network (“CCRAN”) – a patient-focused organization championing the health and wellbeing of Canadians touched by colorectal cancer and others at risk of developing the disease. Her undergraduate and graduate work lie in the biological sciences and educational studies. As a caregiver to her father, who was afflicted with and succumbed to metastatic cancer, his journey has served as the impetus for the founding of CCRAN, one month post his passing in August of 2006. The past seventeen years have been dedicated to the cause of supporting, educating, and advocating on behalf of colorectal cancer patients and caregivers, to improve patients’ quality of life and longevity through the provision of evidence-based information and access to innovative patient programs, such as CCRAN’s innovative “My CRC Consultant”, an online tool providing the metastatic patient with evidence-based and expert reviewed, potential therapeutic options based on the patient’s tumour’s molecular profile. She has been working closely with valued health care professionals across the continuum of colorectal cancer care to ensure content acumen. She is humbled to be published alongside world-renowned experts in areas such as colorectal cancer management, PROs and PROMs, early age onset colorectal cancer awareness and education, promoting national LDLT efforts, education on molecular profiling, and more.

Filomena is a strong proponent of HTA patient evidence submissions since the inception of pCODR, ensuring the patient voice is captured and well incorporated into her submissions. She prepares these submissions not only for colorectal cancer drug therapies under review, but within therapeutic areas for which there are no representative patient advocacy groups or on behalf of patient advocacy groups who may not have the capacity to make these critically important submissions. She strives to secure robust patient and caregiver participation to help identify patients’ unmet needs, as well as capture their fundamentally important values, preferences, and priorities with the goal of ultimately ensuring reimbursement of effective treatments based on thoughtful and compelling input. She continues to be a passionate advocate for the Canadian cancer patient and their caregiver.

Dr. Ramjeesingh holds an MD and PhD from the University of Toronto and completed residency training in internal medicine and medical oncology through Queen’s University. He then undertook a two-year clinical trial methodology and translational research fellowship with the NCIC Clinical Trials Group at Queen’s. His work focused on the appropriate timing of administration of adjuvant chemotherapy to patients with breast cancer.

Dr. Mike Moser completed medical school and surgical residency at the University of Alberta in Canada, then completed a fellowship under the mentorship of Dr. William Wall in London, Ontario in Hepatobiliary Surgery and Transplantation.

Dr. Moser currently practices in Saskatoon, at the University of Saskatchewan as a hepatobiliary and transplant surgeon and maintains a keen interest in tumor ablation and surgical education. Dr. Moser is involved in collaborative research with the Departments of Biomedical Engineering, Chemistry, Oncology, Pharmacology, and Immunology, studying ways of improving the effectiveness of the NanoKnife, while maintaining the relative safety of this novel ablation technology.

‍

Dr. Sharlene Gill is a medical oncologist specializing in gastrointestinal (GI) malignancies at BC Cancer – Vancouver.  She received a BSc. in Pharmacy, and MD from the University of British Columbia in 1996 followed by residencies in Internal Medicine and Medical Oncology, subsequently completing a fellowship in Gl Oncology at the Mayo Clinic (Rochester, MN) and a Masters of Public Health from the Harvard School of Public Health (Boston, MA) before returning to Vancouver where she is presently Professor of Medicine at the University of British Columbia.  In 2017, she completed an MBA from the Kenan-Flagler School of Business at the University of North Carolina.  Her areas of clinical expertise are in colorectal, pancreatic and hepatobiliary cancers.  She is actively engaged in education and clinical research, with over 100 peer-reviewed publications and book chapters to her credit.

‍

Dr. Hallet is an Assistant Professor of Surgery at the University of Toronto and a Surgical Oncologist at the Odette Cancer Centre - Sunnybrook Health Sciences Centre specialized in hepato-biliary, pancreatic and upper gastrointestinal malignancies, with a clinical focus on minimally invasive and image-guided therapies, as well as neuroendocrine tumours as part of the Susan Leslie Multidisciplinary Clinic for Neuroendocrine Tumors. She completed her general surgery residency and MSc in Clinical Epidemiology at Université Laval in Québec City, followed by a Surgical Oncology fellowship in the hepato-pancreatio-biliary track program at the University of Toronto, and additional training in advanced minimally invasive and robotic hepato-pancreatico-biliary surgery at the Institut de recherche contre les cancers de l’appareil digestif (IRCAD) in Strasbourg, France.

As a surgeon investigator, Dr. Hallet’s research focuses on health services research to examine processes, patterns of care, and outcomes of hepato-pancreato-biliary malignancies, with a focus on patient engagement and patient-reported/patient-centred outcomes. In particular, her research is supported by operating grants from the Canadian Institutes of Health Research and the Ontario Institute of Cancer Research, as well as prior early career investigator awards from the Society of Surgery of the Alimentary Tract and the North-American Neuroendocrine Tumors Society.

‍

Dr. Robert Grant is a medical oncologist at Princess Margaret Cancer Centre who treats patients with pancreatic cancer. His research focuses on using machine learning to improve outcomes in oncology.

Popi Kasvis is a Clinical Nutritionist/Dietitian at the McGill University Health Centre in Montreal, working within the multidisciplinary Cancer Rehabilitation Program (CAREPRO). Briefly, her clinical duties include:

1) assessing patients for the presence of malnutrition/sarcopenia/cachexia.

2) creating a nutritional treatment plan to optimize nutritional status.

3) managing nutrition impact symptoms.

Any patient with cancer, including pancreatic cancer, at any stage of disease and into survivorship, may be referred to CAREPRO. Popi received a PhD in the department of Health and Exercise Science at Concordia University. Her research is focused on the effect of early diet and exercise interventions on the health-related quality of life of patients with pancreatic cancer, undergoing both curative and palliative treatments.

‍

Dr. Ramjeesingh holds an MD and PhD from the University of Toronto and completed residency training in internal medicine and medical oncology through Queen’s University. He then undertook a two-year clinical trial methodology and translational research fellowship with the NCIC Clinical Trials Group at Queen’s. His work focused on the appropriate timing of administration of adjuvant chemotherapy to patients with breast cancer.

‍

Dr. Mark Walsh MD MSc FRCSC is a Hepato-Pancreatico-Biliary surgeon at the QEII Health Sciences Centre and an Assistant Professor and Director of Quality Improvement at Dalhousie University, in Nova Scotia Canada.

Dr. Jeanette Boudreau received her PhD from McMaster University and completed post-doctoral training at Memorial Sloan Kettering Cancer Center. Dr. Boudreau’s laboratory focuses on human natural killer cells as indicators and tools for cancer immunotherapy. Her group is interested in both the genetic and functional aspects of pancreatic cancer and the immune system, and how they factor into development and treatment of cancer. The Boudreau laboratory uses high-parameter flow cytometry, microscopy and humanized animal models to study immune-tumor interactions.

‍

Mustapha Tehfe is a professor in the Department of Medicine at the University of Montreal and hemato-oncologist at the Center hospitalier de l'Université de Montréal (CHUM).

‍

George Zogopoulos, MD (Toronto), PhD (McGill) is an Associate Professor of Surgery and Oncology at McGill University, a staff surgeon at the McGill University Health Centre (MUHC), and a scientist at the Research Institute of the MUHC and the Rosalind and Morris Goodman Cancer Institute. He is a senior clinical research scholar of the Fonds de recherche du Québec - Santé and recipient of the Michal & Renata Hornstein Career Award for Surgical Excellence, with a translational research program studying the genetics and oncogenomics of pancreaticobiliary cancers. His clinical practice focuses on the surgical treatment of pancreatic, biliary and hepatic malignancies as well as abdominal organ transplantation with an interest in transplant oncology.